Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells.
暂无分享,去创建一个
Sushovan Guha | Naomi J Halas | Amit Deorukhkar | Sunil Krishnan | Rizia Bardhan | Lisa V. Brown | N. Halas | R. Pautler | C. Pérez-Torres | S. Guha | B. Ji | R. Bardhan | Amit Joshi | S. Krishnan | N. Biswal | Xian-de Liu | C. Ayala-Orozco | Wenxue Chen | Ciceron Ayala-Orozco | Nrusingh C Biswal | Carlos Perez-Torres | Marc Bartels | Gary Stinnet | Xian-De Liu | Baoan Ji | Lisa V Brown | Robia G Pautler | Amit Joshi | L. Brown | A. Deorukhkar | M. Bartels | Wenxue Chen | Gary R Stinnet
[1] Mostafa A. El-Sayed,et al. Beating cancer in multiple ways using nanogold. , 2011, Chemical Society reviews.
[2] A. Naylor,et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. , 2000, Stroke.
[3] A. Leonardi,et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells , 2008, Proceedings of the National Academy of Sciences.
[4] M. Goumans,et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: a protein associated with unstable human plaque characteristics. , 2011, Cardiovascular research.
[5] Philippe C. Besse,et al. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. , 2006, World journal of gastroenterology.
[6] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[7] S. Ohlson,et al. Interactions between neutrophil gelatinase-associated lipocalin and natural lipophilic ligands. , 1999, Biochimica et biophysica acta.
[8] Robia G. Pautler,et al. Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo. , 2010, Nano letters.
[9] Naomi J Halas,et al. Theranostic nanoshells: from probe design to imaging and treatment of cancer. , 2011, Accounts of chemical research.
[10] L. Kjeldsen,et al. Subcellular localization and translocation of the receptor for N-formylmethionyl-leucyl-phenylalanine in human neutrophils. , 1994, The Biochemical journal.
[11] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[12] Jun Li,et al. Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer* , 2010, The Journal of Biological Chemistry.
[13] Susan M. Kilroy,et al. Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase Species , 2008, Clinical Cancer Research.
[14] E. Raines,et al. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. , 2005, The Journal of clinical investigation.
[15] M. Mizumoto,et al. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. , 1998, Cancer letters.
[16] Valery V Tuchin,et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery , 2009, Journal of biophotonics.
[17] Robia G. Pautler,et al. Nanoshells with Targeted Simultaneous Enhancement of Magnetic and Optical Imaging and Photothermal Therapeutic Response , 2009 .
[18] J. D. Payne,et al. Application of INAA to the build-up and clearance of gold nanoshells in clinical studies in mice , 2007 .
[19] L. Pusztai,et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. , 2009, Cancer research.
[20] Naomi J Halas,et al. A Molecularly Targeted Theranostic Probe for Ovarian Cancer , 2010, Molecular Cancer Therapeutics.
[21] Douglas B. Evans,et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.
[22] B. Aggarwal,et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. , 2008, Cancer research.
[23] G. Rice,et al. Neutrophil gelatinase‐associated lipocalin (NGAL) an early‐screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor‐induced epithelio‐mesenchymal transition , 2007, International journal of cancer.
[24] K. Mori,et al. Dual action of neutrophil gelatinase-associated lipocalin. , 2007, Journal of the American Society of Nephrology : JASN.
[25] Tammy Y. Olson,et al. Synthesis, characterization, and tunable optical properties of hollow gold nanospheres. , 2006, The journal of physical chemistry. B.
[26] S. Nie,et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. , 2009, Gastroenterology.
[27] Naomi J. Halas,et al. Nanosphere-in-a-Nanoshell: A Simple Nanomatryushka† , 2010 .
[28] S. Batra,et al. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin , 2009, British Journal of Cancer.
[29] I. Shmulevich,et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells , 2009, Laboratory Investigation.
[30] Eva M. Sevick-Muraca,et al. Improved Excitation Light Rejection Enhances Small-Animal Fluorescent Optical Imaging , 2005, Molecular imaging.
[31] J. Cameron,et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. , 2001, Cancer research.
[32] D. Winchester,et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. , 1999, Journal of the American College of Surgeons.
[33] Glenn P. Goodrich,et al. Evaluation of the Toxicity of Intravenous Delivery of Auroshell Particles (Gold–Silica Nanoshells) , 2012, International journal of toxicology.
[34] P Ghaneh,et al. Biology and management of pancreatic cancer , 2008, Postgraduate Medical Journal.
[35] Christine A Iacobuzio-Donahue,et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. , 2003, Cancer research.
[36] D. Zurakowski,et al. Lipocalin 2 promotes breast cancer progression , 2009, Proceedings of the National Academy of Sciences.
[37] Haiyong Han,et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. , 2002, Cancer research.
[38] S. Batra,et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia , 2008, British Journal of Cancer.
[39] Eithne Costello,et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis , 2004, International journal of cancer.
[40] P. Kulkarni,et al. Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution. , 2010, Nanomedicine.
[41] Douglas B. Evans,et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation , 2006, Cancer.
[42] B. Nielsen,et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. , 1996, Gut.